CagriSema
Premium API
CagriSema API
CagriSema (Cargrilintide/Semaglutide) is the fixed-dose combination of cagrilintide and semaglutide. It is currently in trial and not available for prescription. CagriSema has the potential to lose weight and improve blood sugar control, especially for individuals with obesity and type 2 diabetes.
Premium API
CagriSema
With addition of cagrilintide(a long-acting amylin analog) to semaglutide, CagriSema provides better efficacy than semaglutide(Ozempic, Wegovy) and tirzepatide(Mounjaro, Zepbound) for both obesity and T2DM. As the next-generation GLP-1 agent, it combines the known advantages of GLP-1s with the activity of amylin. Once approved, it will be the first FDC(fixed-dose combinations) amylin and GLP-1 RA(Glucagon-like peptide-1 receptor agonists).
US -FDA
DMF Certificate
Morebio achieves the FDA-DMF certificate for Semaglutide API (039115), Semaglutide Main Chain (039480).
Semaglutide API
DMF 039115
Semaglutide Main Chain
DMF 039480
Premium API
CagriSema Description
CagriSema (Cargrilintide/Semaglutide) has greater weight loss than either semaglutide or cagrilintide alone in preliminary trial results. The HbA1c has a significant increase compared to cagrilintide alone, but is no better than semaglutide alone. In the phase II trial, CagriSema has similar efficacy to tirzepatide.
